GEMTESA may help
you score OAB
symptom relief
GEMTESA may help you score OAB symptom relief
Proven results
GEMTESA is the first and only FDA-approved medication to treat OAB (overactive bladder) in men being treated for BPH (benign prostatic hyperplasia) who experience:
- Urges so strong that they could be followed by leakage
- Unusually strong urges to urinate
- Frequent urination (8 or more times per day)
Convenient dosing
A once-daily treatment for OAB in men receiving BPH treatment.
An option if you have high blood pressure
No clinically significant changes to hypertension or increased blood pressure were seen vs placebo.
- In a study of OAB in men being treated for BPH, rates of hypertension were 9.0% with GEMTESA (50 of 553 people) vs 8.3% with placebo (46 of 551 people).
- In a separate clinical study of men and women, people taking GEMTESA and those taking placebo had similar rates of hypertension (1.7% [9 out of 545 people] vs 1.7% [9 out of 540 people], respectively) and increased blood pressure (0.7% [4 out of 545 people] vs 0.9% [5 out of 540 people], respectively).
Proven safety profile
GEMTESA has a proven safety profile and won’t interact with medications commonly taken for other conditions, including BPH treatments.
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements, or if you take medications that contain digoxin.
Talk to your doctor about GEMTESA — the first and only FDA-approved treatment for OAB symptoms that you can take with your BPH medication.
REMEMBER:
There’s only one GEMTESA and no generic substitute. When you fill your prescription, make sure you receive the brand name.
At 12 weeks, men taking GEMTESA had to go less often, had fewer “urge to go” bathroom visits, and had fewer leakage episodes
GEMTESA is the only OAB treatment proven to reduce all 3 key symptoms (urgency, frequency, and leakage) in men treated for BPH
In a clinical trial, most men with BPH taking GEMTESA saw significant reduction in all OAB symptoms at 12 weeks of consistent use as prescribed.*
fewer daily leakage episodes
An OAB treatment that may help that “can’t hold it in” feeling
- Men with BPH taking GEMTESA had about 2 (-2.19) fewer daily leakage episodes on average compared with about 1 (-1.39) fewer episode for those taking placebo†
fewer bathroom visits with
"urge to go" feelings
Stay on the go, with less urgency to go
- Men with BPH taking GEMTESA had nearly 3 (-2.88) fewer bathroom visits with “urge to go” feelings on average compared with about 2 (-1.93) fewer visits for those taking placebo‡
fewer bathroom visits
Fewer bathroom visits mean fewer daily interruptions
- Men with BPH taking GEMTESA had about 2 (-2.04) fewer bathroom visits per day on average compared with about 1 (-1.3) less visit per day for those taking placebo‡
*The safety and efficacy of GEMTESA were studied in a 24-week trial in male patients with OAB being treated for BPH.
†146 people received GEMTESA and 151 people received placebo.
‡538 people received GEMTESA and 542 people received placebo.
Ready to learn more about what to expect on GEMTESA?
See Safety Profile
